Shenzhen

[키워드] acute respiratory distress acute respiratory syndrome Administered administration Admission age Antiviral antiviral agent Antiviral treatment approach ARDS assessment binding blood biochemical body temperature case sery change China Chinese patient clinical Clinical outcome clinical status clinical trials conducted convalescent plasma coronavirus coronavirus disease Coronavirus disease 2019 COVID-19 Critical Critically ill patient determine Dilution discharged ECMO Effectiveness ELISA end point enzyme-linked immunosorbent exposure extracorporeal membrane oxygenation failure Final finding Follow-up greater hospital Human plasma IgG Ill Importance Infection Infectious disease laboratory-confirmed limited sample size measure mechanical ventilation Methylprednisolone Mortality neutralization titer neutralizing antibody Neutralizing antibody titer normalized objective observation outcome pandemic participant Patient patients plasma Plasma transfusion Point preliminary finding progression raise randomized clinical trials receiving recovered patients Relevance resolved Result SARS-CoV-2 SARS-CoV-2 antibody SARS-CoV-2–specific antibody serum antibody setting severe pneumonia Shenzhen SOFA SOFA score Study design Support syndrome therapeutic agent treated Treatment ventilatory Viral load were given with COVID-19 women
[DOI] 10.1001/jama.2020.4783 PMC 바로가기 [Article Type] Research